Actinium Pharmaceuticals Inc (ATNM) Unusual Options Activity Today

Checking ATNM unusual options activity helps you spot when traders are making outsized bets on Actinium Pharmaceuticals Inc before the broader market catches on. Actinium Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ATNM unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ATNM unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ATNM unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ATNM unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities.

It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Catalysts rarely arrive without a footprint, and ATNM unusual options activity is often where that footprint shows up first. Our scanner tracks Actinium Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ATNM unusual options volume on the call side or chasing put sweeps, Actinium Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.